Detalhe da pesquisa
1.
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study).
Cancer Immunol Immunother
; 72(1): 91-99, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35729418
2.
Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study.
Cancer Immunol Immunother
; 71(7): 1719-1731, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34821950
3.
First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.
Future Oncol
; 17(23): 3007-3016, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34156285
4.
Compliance to regional recommendations for molecular analyses and management of advanced lung cancer patients.
Future Oncol
; 15(18): 2139-2149, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31185741
5.
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial.
Eur Respir J
; 52(4)2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30262574
6.
Resected EGFR-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study).
Ther Adv Med Oncol
; 16: 17588359241236451, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38455711
7.
Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.
Target Oncol
; 18(4): 585-591, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37310660
8.
Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer.
J Cancer Res Clin Oncol
; 149(16): 15095-15102, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37626173
9.
Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 study.
J Geriatr Oncol
; : 101506, 2023 May 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37211514
10.
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).
Target Oncol
; 18(6): 905-914, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37966566
11.
Three-Year Overall Survival of Patients With Advanced Non-Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study).
J Immunother
; 2023 Oct 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37807621
12.
Immune-related generalised oedema - A new category of adverse events with immune checkpoint inhibitors.
Eur J Cancer
; 179: 28-47, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36473326
13.
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018.
Eur J Cancer
; 183: 38-48, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36801605
14.
Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer.
J Thorac Oncol
; 18(10): 1408-1415, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37217096
15.
FDG PET and CT radiomics in diagnosis and prognosis of non-small-cell lung cancer.
Transl Lung Cancer Res
; 11(10): 2051-2063, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36386457
16.
[Semantic analysis of online conversations on lung cancer: The WE-Lung research]. / Analyse sémantique de conversations sur le web portant sur le cancer du poumon : étude Web Ethnography-Lung.
Bull Cancer
; 109(7-8): 805-816, 2022.
Artigo
em Francês
| MEDLINE | ID: mdl-35599172
17.
Paclitaxel-bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study.
Ther Adv Med Oncol
; 14: 17588359221099399, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35694190
18.
Durvalumab-induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non-small cell lung cancer: A case report.
Thorac Cancer
; 12(8): 1240-1243, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33624409
19.
Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus "at progression" cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis.
Ther Adv Med Oncol
; 13: 17588359211006983, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33948123
20.
Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
Cancer Med
; 9(2): 432-439, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31747137